FDA de novo clearance

23andMe raises $79 million as it shifts focus to research, drug development
By Jonah Comstock | 10:34 am | July 06, 2015
According to an SEC filing, mail-order personal genome service and research company 23andMe has raised $79 million, in a round the company hopes will top out at $150 million.